Get the Stockscreener App
39.80
0.53%
-0.2261
Harrow Inc stock is traded at $39.80, with a volume of 225.65K.
It is down -0.53% in the last 24 hours and down -14.65% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$40.03
Open:
$39.21
24h Volume:
225.65K
Relative Volume:
0.31
Market Cap:
$1.49B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-243.45
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
-2.17%
1M Performance:
-14.65%
6M Performance:
-21.22%
1Y Performance:
+2.57%
1-Day Range:
$39.05
$40.32
1-Week Range:
$37.70
$43.00
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
39.83 | 1.50B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.46 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.585 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.56 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.39 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - marketbeat.com
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - marketbeat.com
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - marketbeat.com
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth - Sahm
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - marketbeat.com
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Releases Q2 2026 Financial Results - AlphaStreet
Harrow Q2 Earnings Call Highlights - marketbeat.com
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - marketbeat.com
Harrow Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harrow, Inc. (HROW) Q2 FY2026 earnings call transcript - Yahoo Finance
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline - TradingView
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story - simplywall.st
HROW Looks 8.5% Undervalued on GF Value™ - GuruFocus
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Harrow affirms FY26 sales guidance of $350-365M vs $348.468M est - scanx.trade
HROW Looks 8.5% Undervalued on GF Value™ Amid Mixed Growth Signa - GuruFocus
Harrow, Inc. Announces $17.3 Million Net Loss in Q2 2026 Amid Revenue Growth - Kalkine Media
Harrow: Q2 Earnings Snapshot - marketscreener.com
Is Harrow Inc (HROW) Positioned for Growth After Q2 Earnings Rep - GuruFocus
Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS - marketbeat.com
Harrow, Inc. Releases Q2 2026 Earnings and Corporate Update - Kalkine Media
Harrow Q2 Swings to Loss, Revenue Rises - marketscreener.com
Harrow, Inc. (HROW) stock falls on Q2 2026 Earnings - Quiver Quantitative
Harrow Q2 Results: EPS Misses Estimate, Sales Rise 10.85% YoY - scanx.trade
(HROW) Harrow Expects Full Year 2026 Revenue Range $350M$365M, vs. FactSet Est of $348.5M - marketscreener.com
Earnings Flash (HROW) Harrow Posts Q2 Loss $0.46, vs. FactSet Est of $0.18 Loss - marketscreener.com
Harrow, Inc. (HROW) grows branded eyecare sales as losses and debt increase - Stock Titan
HROW: Q2 revenue surged 60% sequentially, with robust product growth and guidance reaffirmed - TradingView
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, vs. FactSet Est of $70.4M - marketscreener.com
Harrow Announces Second Quarter 2026 Financial Results - The Manila Times
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M - Moomoo
BRIEF-Harrow Inc Q2 Gross Margin 71% - TradingView
Harrow, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback? By Investing.com - Investing.com UK
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback? - Investing.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
1.76%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):